ESBA1008 solution

DRUG3 trials

Sponsors

Alcon Research

Conditions

Exudative Age-Related Macular Degeneration

Phase 1

ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients

CompletedNCT01304693

Alcon ResearchExudative Age-Related Macular Degeneration

Start: 2010-10-31End: 2013-03-31Updated: 2014-07-17

Phase 2

Efficacy and Safety Study of ESBA1008 Versus EYLEA®

CompletedNCT01796964

Alcon ResearchExudative Age-Related Macular Degeneration

Start: 2013-03-31End: 2014-08-31Updated: 2016-02-09

ESBA1008 Microvolume Study

CompletedNCT01849692

Alcon ResearchExudative Age-Related Macular Degeneration

Start: 2013-06-30End: 2015-01-31Updated: 2016-03-24